Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients

Detalhes bibliográficos
Autor(a) principal: Gonçalves-Pereira, João
Data de Publicação: 2014
Outros Autores: Silva, Nuno Elvas, Mateus, André, Pinho, Catarina, Povoa, Pedro
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/23248
Resumo: Background: Meropenem is a carbapenem antibiotic commonly used in critically ill patients to treat severe infections. The available pharmacokinetic (PK) data has been mostly obtained from healthy volunteers as well as from clinical studies addressing selected populations, often excluding the elderly and also patients with renal failure. Our aim was to study PK of meropenem in a broader population of septic critically ill patients. Methods: We characterized the PK of meropenem in 15 critically ill patients during the first 36 hrs of therapy. Aditionally, whenever possible, we collected a second set of late plasma samples after 5 days of therapy to evaluate PK intra-patient variability and its correlation with clinical course. Patients received meropenem (1 g every 8 hrs IV). Drug plasma profiles were determined by high-performance liquid chromatography. The PK of meropenem was characterized and compared with clinical parameters. Results: Fifteen septic critically ill patients (8 male, median age 73 yrs) were included. The geometric mean of the volume of distribution at the steady state (V-ss)/weight was 0.20 (0.15-0.27) L/kg. No correlation of Vss/weight with severity or comorbidity scores was found. However the Sequential Organ Failure Assessment score correlated with the Vss/ weight of the peripheral compartment (r(2) = 0.55, p = 0.021). The median meropenem clearance (Cl) was 73.3 (45-120) mL/min correlated with the creatinine (Cr) Cl (r(2)=0.35, p = 0.033). After 5 days (N = 7) although Vss remained stable, a decrease in the proportion of the peripheral compartment (V-ss2) was found, from 61.3 (42.5-88.5)\% to 51.7 (36.6-73.1)\%. No drug accumulation was noted. Conclusions: In this cohort of septic, unselected, critically ill patients, large meropenem PK heterogeneity was noted, although neither underdosing nor accumulation was found. However, Cr Cl correlated to meropenem Cl and the Vss2 decreased with patient's improvement.
id RCAP_d552861694d3ebab304979faadf36db4
oai_identifier_str oai:run.unl.pt:10362/23248
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsAUGMENTED RENAL CLEARANCESEVERE INFECTIONSCONTROLLED-TRIALSEVERE SEPSISIntensive care unitSHOCKBETA-LACTAM CONCENTRATIONSPHARMACODYNAMICSMULTICENTERPharmacokineticsMeropenembeta-lactam antibioticsANTIBIOTIC-THERAPYVENTILATOR-ASSOCIATED PNEUMONIAMeropenembeta-lactam antibioticsPharmacokineticsIntensive care unitRM Therapeutics. PharmacologyRS Pharmacy and materia medicaBackground: Meropenem is a carbapenem antibiotic commonly used in critically ill patients to treat severe infections. The available pharmacokinetic (PK) data has been mostly obtained from healthy volunteers as well as from clinical studies addressing selected populations, often excluding the elderly and also patients with renal failure. Our aim was to study PK of meropenem in a broader population of septic critically ill patients. Methods: We characterized the PK of meropenem in 15 critically ill patients during the first 36 hrs of therapy. Aditionally, whenever possible, we collected a second set of late plasma samples after 5 days of therapy to evaluate PK intra-patient variability and its correlation with clinical course. Patients received meropenem (1 g every 8 hrs IV). Drug plasma profiles were determined by high-performance liquid chromatography. The PK of meropenem was characterized and compared with clinical parameters. Results: Fifteen septic critically ill patients (8 male, median age 73 yrs) were included. The geometric mean of the volume of distribution at the steady state (V-ss)/weight was 0.20 (0.15-0.27) L/kg. No correlation of Vss/weight with severity or comorbidity scores was found. However the Sequential Organ Failure Assessment score correlated with the Vss/ weight of the peripheral compartment (r(2) = 0.55, p = 0.021). The median meropenem clearance (Cl) was 73.3 (45-120) mL/min correlated with the creatinine (Cr) Cl (r(2)=0.35, p = 0.033). After 5 days (N = 7) although Vss remained stable, a decrease in the proportion of the peripheral compartment (V-ss2) was found, from 61.3 (42.5-88.5)\% to 51.7 (36.6-73.1)\%. No drug accumulation was noted. Conclusions: In this cohort of septic, unselected, critically ill patients, large meropenem PK heterogeneity was noted, although neither underdosing nor accumulation was found. However, Cr Cl correlated to meropenem Cl and the Vss2 decreased with patient's improvement.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)RUNGonçalves-Pereira, JoãoSilva, Nuno ElvasMateus, AndréPinho, CatarinaPovoa, Pedro2017-09-14T22:01:09Z2014-04-142014-04-14T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article7application/pdfhttp://hdl.handle.net/10362/23248eng1471-2210PURE: 384380https://doi.org/10.1186/2050-6511-15-21info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:11:29Zoai:run.unl.pt:10362/23248Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:27:43.407317Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
title Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
spellingShingle Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
Gonçalves-Pereira, João
AUGMENTED RENAL CLEARANCE
SEVERE INFECTIONS
CONTROLLED-TRIAL
SEVERE SEPSIS
Intensive care unit
SHOCK
BETA-LACTAM CONCENTRATIONS
PHARMACODYNAMICS
MULTICENTER
Pharmacokinetics
Meropenem
beta-lactam antibiotics
ANTIBIOTIC-THERAPY
VENTILATOR-ASSOCIATED PNEUMONIA
Meropenem
beta-lactam antibiotics
Pharmacokinetics
Intensive care unit
RM Therapeutics. Pharmacology
RS Pharmacy and materia medica
title_short Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
title_full Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
title_fullStr Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
title_full_unstemmed Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
title_sort Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
author Gonçalves-Pereira, João
author_facet Gonçalves-Pereira, João
Silva, Nuno Elvas
Mateus, André
Pinho, Catarina
Povoa, Pedro
author_role author
author2 Silva, Nuno Elvas
Mateus, André
Pinho, Catarina
Povoa, Pedro
author2_role author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Centro de Estudos de Doenças Crónicas (CEDOC)
RUN
dc.contributor.author.fl_str_mv Gonçalves-Pereira, João
Silva, Nuno Elvas
Mateus, André
Pinho, Catarina
Povoa, Pedro
dc.subject.por.fl_str_mv AUGMENTED RENAL CLEARANCE
SEVERE INFECTIONS
CONTROLLED-TRIAL
SEVERE SEPSIS
Intensive care unit
SHOCK
BETA-LACTAM CONCENTRATIONS
PHARMACODYNAMICS
MULTICENTER
Pharmacokinetics
Meropenem
beta-lactam antibiotics
ANTIBIOTIC-THERAPY
VENTILATOR-ASSOCIATED PNEUMONIA
Meropenem
beta-lactam antibiotics
Pharmacokinetics
Intensive care unit
RM Therapeutics. Pharmacology
RS Pharmacy and materia medica
topic AUGMENTED RENAL CLEARANCE
SEVERE INFECTIONS
CONTROLLED-TRIAL
SEVERE SEPSIS
Intensive care unit
SHOCK
BETA-LACTAM CONCENTRATIONS
PHARMACODYNAMICS
MULTICENTER
Pharmacokinetics
Meropenem
beta-lactam antibiotics
ANTIBIOTIC-THERAPY
VENTILATOR-ASSOCIATED PNEUMONIA
Meropenem
beta-lactam antibiotics
Pharmacokinetics
Intensive care unit
RM Therapeutics. Pharmacology
RS Pharmacy and materia medica
description Background: Meropenem is a carbapenem antibiotic commonly used in critically ill patients to treat severe infections. The available pharmacokinetic (PK) data has been mostly obtained from healthy volunteers as well as from clinical studies addressing selected populations, often excluding the elderly and also patients with renal failure. Our aim was to study PK of meropenem in a broader population of septic critically ill patients. Methods: We characterized the PK of meropenem in 15 critically ill patients during the first 36 hrs of therapy. Aditionally, whenever possible, we collected a second set of late plasma samples after 5 days of therapy to evaluate PK intra-patient variability and its correlation with clinical course. Patients received meropenem (1 g every 8 hrs IV). Drug plasma profiles were determined by high-performance liquid chromatography. The PK of meropenem was characterized and compared with clinical parameters. Results: Fifteen septic critically ill patients (8 male, median age 73 yrs) were included. The geometric mean of the volume of distribution at the steady state (V-ss)/weight was 0.20 (0.15-0.27) L/kg. No correlation of Vss/weight with severity or comorbidity scores was found. However the Sequential Organ Failure Assessment score correlated with the Vss/ weight of the peripheral compartment (r(2) = 0.55, p = 0.021). The median meropenem clearance (Cl) was 73.3 (45-120) mL/min correlated with the creatinine (Cr) Cl (r(2)=0.35, p = 0.033). After 5 days (N = 7) although Vss remained stable, a decrease in the proportion of the peripheral compartment (V-ss2) was found, from 61.3 (42.5-88.5)\% to 51.7 (36.6-73.1)\%. No drug accumulation was noted. Conclusions: In this cohort of septic, unselected, critically ill patients, large meropenem PK heterogeneity was noted, although neither underdosing nor accumulation was found. However, Cr Cl correlated to meropenem Cl and the Vss2 decreased with patient's improvement.
publishDate 2014
dc.date.none.fl_str_mv 2014-04-14
2014-04-14T00:00:00Z
2017-09-14T22:01:09Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/23248
url http://hdl.handle.net/10362/23248
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1471-2210
PURE: 384380
https://doi.org/10.1186/2050-6511-15-21
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 7
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137904458465280